A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F09%3A6882" target="_blank" >RIV/00064203:_____/09:6882 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/09:00002567 RIV/00216208:11130/09:6882
Result on the web
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19880844" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/19880844</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Original language description
Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in thesepatients has not been adequately tested.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
361
Issue of the periodical within the volume
21
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
2019-2032
UT code for WoS article
000271898600007
EID of the result in the Scopus database
—